SCHEMBL980864

SCHEMBL980864

COC(=O)n1ccc2cc(C3CC(=O)N(Cc4ccccc4)C3=O)ccc21

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 3/20 0.42
POLB P06746 2/20 0.41
ALDH1A1 P00352 7/20 0.41
GAA P10253 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
STAT6 P42226 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 2/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.38
LMNA P02545 1/20 0.38
GSK3B P49841 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981418 0.92 ALDH1A1 (0.42) GPBAR1POLBALDH1A1GAACYP1A2
SCHEMBL982774 0.87 GPBAR1 (0.41) GPBAR1POLBALDH1A1GAACYP1A2
SCHEMBL983012 0.81 CYP19A1 (0.45) GPBAR1ALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL982927 0.74 PTGDR2 (0.40) KMT2AMEN1
SCHEMBL981672 0.72 ATM (0.40) KMT2AMEN1
SCHEMBL3602720 0.72 ALDH1A1 (0.59) POLBALDH1A1GAACYP1A2CYP3A4
SCHEMBL2777419 0.71 NR4A2 (0.49) GPBAR1ALDH1A1GAACYP1A2CYP3A4
SCHEMBL2778056 0.71 NR4A2 (0.47) GPBAR1ALDH1A1GAACYP1A2CYP3A4
SCHEMBL984991 0.71 PTGDR2 (0.38) ALDH1A1KMT2AMEN1
SCHEMBL25890038 0.71 ALDH1A1 (0.62) GPBAR1POLBALDH1A1GAACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 GPBAR1 1162/4885POLB 1806/4885ALDH1A1 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.